Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data
Executive Summary
FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said
You may also be interested in...
Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July
FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated
Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July
FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4